These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24533447)

  • 1. An investigation of the impact of futility analysis in publicly funded trials.
    Sully BG; Julious SA; Nicholl J
    Trials; 2014 Feb; 15():61. PubMed ID: 24533447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A reinvestigation of recruitment to randomised, controlled, multicenter trials: a review of trials funded by two UK funding agencies.
    Sully BG; Julious SA; Nicholl J
    Trials; 2013 Jun; 14():166. PubMed ID: 23758961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stopping clinical trials early for futility: retrospective analysis of several randomised clinical studies.
    Jitlal M; Khan I; Lee SM; Hackshaw A
    Br J Cancer; 2012 Sep; 107(6):910-7. PubMed ID: 22878376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of futility monitoring guidelines using completed phase III oncology trials.
    Zhang Q; Freidlin B; Korn EL; Halabi S; Mandrekar S; Dignam JJ
    Clin Trials; 2017 Feb; 14(1):48-58. PubMed ID: 27590208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upstrapping to determine futility: predicting future outcomes nonparametrically from past data.
    Wild JL; Ginde AA; Lindsell CJ; Kaizer AM
    Trials; 2024 May; 25(1):312. PubMed ID: 38725072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic survey of randomised trials that stopped early for reasons of futility.
    Walter SD; Han H; Guyatt GH; Bassler D; Bhatnagar N; Gloy V; Schandelmaier S; Briel M
    BMC Med Res Methodol; 2020 Jan; 20(1):10. PubMed ID: 31948397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal timing for an accelerated interim futility analysis incorporating real world data.
    Haine LMF; Murray TA; Koopmeiners JS
    Contemp Clin Trials; 2024 May; 140():107489. PubMed ID: 38461938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A flexible futility monitoring method with time-varying conditional power boundary.
    Ying Zhang ; Clarke WR
    Clin Trials; 2010 Jun; 7(3):209-18. PubMed ID: 20423927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Operating characteristics of sample size re-estimation with futility stopping based on conditional power.
    Lachin JM
    Stat Med; 2006 Oct; 25(19):3348-65. PubMed ID: 16345019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantifying the bias in the estimated treatment effect in randomized trials having interim analyses and a rule for early stopping for futility.
    Walter SD; Han H; Briel M; Guyatt GH
    Stat Med; 2017 Apr; 36(9):1506-1518. PubMed ID: 28183155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimality criteria for futility stopping boundaries for group sequential designs with a continuous endpoint.
    Li X; Herrmann C; Rauch G
    BMC Med Res Methodol; 2020 Nov; 20(1):274. PubMed ID: 33153438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Choice of futility boundaries for group sequential designs with two endpoints.
    Schüler S; Kieser M; Rauch G
    BMC Med Res Methodol; 2017 Aug; 17(1):119. PubMed ID: 28789615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budgeting of non-commercial clinical trials: development of a budget tool by a public funding agency.
    Nevens H; Harrison J; Vrijens F; Verleye L; Stocquart N; Marynen E; Hulstaert F
    Trials; 2019 Dec; 20(1):714. PubMed ID: 31829233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Over-accrual in Bayesian adaptive trials with continuous futility stopping.
    Barrado LG; Burzykowski T
    Clin Trials; 2023 Jun; 20(3):252-260. PubMed ID: 36803007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
    Lachin JM
    Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Futility stopping in clinical trials, optimality and practical considerations.
    Chang Y; Song T; Monaco J; Ivanova A
    J Biopharm Stat; 2020 Nov; 30(6):1050-1059. PubMed ID: 32926648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Applying a phase II futility study design to therapeutic stroke trials.
    Palesch YY; Tilley BC; Sackett DL; Johnston KC; Woolson R
    Stroke; 2005 Nov; 36(11):2410-4. PubMed ID: 16224086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of futility in clinical trials.
    Snapinn S; Chen MG; Jiang Q; Koutsoukos T
    Pharm Stat; 2006; 5(4):273-81. PubMed ID: 17128426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative views on setting clinical trial futility criteria.
    Gallo P; Mao L; Shih VH
    J Biopharm Stat; 2014; 24(5):976-93. PubMed ID: 24933121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview, hurdles, and future work in adaptive designs: perspectives from a National Institutes of Health-funded workshop.
    Coffey CS; Levin B; Clark C; Timmerman C; Wittes J; Gilbert P; Harris S
    Clin Trials; 2012 Dec; 9(6):671-80. PubMed ID: 23250942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.